Published in Leuk Res on September 22, 2010
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood (2013) 1.50
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene (2013) 0.81
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun (2005) 6.31
Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol (2007) 4.75
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (1981) 4.25
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res (2008) 2.79
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol (2002) 2.66
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc Natl Acad Sci U S A (2004) 2.21
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08
T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A (2007) 2.06
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol (2008) 1.98
MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res (1999) 1.90
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res (2008) 1.74
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res (2004) 1.52
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma (2003) 1.50
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol (1996) 1.45
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2009) 1.39
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother (2007) 1.38
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
Superantigen-induced T cell:B cell conjugation is mediated by LFA-1 and requires signaling through Lck, but not ZAP-70. J Immunol (2001) 1.30
Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother (2006) 1.30
Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol (2006) 1.24
Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery (2008) 1.13
Epstein-Barr virus (EBV) can immortalize B-cll cells activated by cytokines. Leukemia (1994) 1.11
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother (2005) 1.00
An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med (2007) 0.99
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol (2010) 0.99
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother (2004) 0.95
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets (2007) 0.93
Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol (2006) 0.92
Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol (2007) 0.91
Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol (2002) 0.90
Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol (2007) 0.88
Natural killer function in flow cytometry: identification of human lymphoid subsets able to bind to the NK sensitive target K562. Cytometry (1991) 0.81
Mitochondria control calcium entry at the immunological synapse. Proc Natl Acad Sci U S A (2007) 0.80
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80
Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol (1997) 0.78
Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma (2007) 0.77
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
WormBase: better software, richer content. Nucleic Acids Res (2006) 6.78
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
WormBase: a comprehensive resource for nematode research. Nucleic Acids Res (2009) 5.20
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Stimulus onset quenches neural variability: a widespread cortical phenomenon. Nat Neurosci (2010) 4.69
Stimulus dependence of neuronal correlation in primary visual cortex of the macaque. J Neurosci (2005) 4.04
WormBase: new content and better access. Nucleic Acids Res (2006) 4.01
WormBase 2012: more genomes, more data, new website. Nucleic Acids Res (2011) 3.87
WormBase 2007. Nucleic Acids Res (2007) 3.69
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol (2004) 3.39
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
WormBase 2014: new views of curated biology. Nucleic Acids Res (2013) 2.39
Traffic-related air pollution and acute changes in heart rate variability and respiratory function in urban cyclists. Environ Health Perspect (2011) 2.12
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res (2011) 2.10
Comparison of recordings from microelectrode arrays and single electrodes in the visual cortex. J Neurosci (2007) 2.05
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol (2008) 1.98
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
Correlations and brain states: from electrophysiology to functional imaging. Curr Opin Neurobiol (2009) 1.62
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma (2011) 1.47
Stimulus selectivity and spatial coherence of gamma components of the local field potential. J Neurosci (2011) 1.33
The timing of response onset and offset in macaque visual neurons. J Neurosci (2002) 1.33
Local field potentials indicate network state and account for neuronal response variability. J Comput Neurosci (2010) 1.31
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood (2004) 1.30
Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol (2003) 1.22
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest (2014) 1.16
The role of correlations in direction and contrast coding in the primary visual cortex. J Neurosci (2007) 1.16
The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol (2010) 1.14
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2005) 1.13
SCHEMA recombination of a fungal cellulase uncovers a single mutation that contributes markedly to stability. J Biol Chem (2009) 1.11
PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol (2010) 1.11
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem (2011) 1.04
MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J (2010) 1.03
Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood (2012) 1.00
Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program (2007) 1.00
JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep (2013) 0.99
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diagn Pathol (2012) 0.99
Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk (2011) 0.98
Circumventing immune tolerance through epigenetic modification. Curr Pharm Des (2010) 0.97
Identification of a novel negative role of flagellin in regulating IL-10 production. Eur J Immunol (2007) 0.97
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem (2012) 0.97
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res (2012) 0.94
Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Mol Immunol (2005) 0.94
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol Immunol (2006) 0.93
Innovation by homologous recombination. Curr Opin Chem Biol (2013) 0.93
Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets (2007) 0.93
Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J Immunol (2013) 0.93
High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery (2006) 0.93
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res (2013) 0.92
Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett (2010) 0.92
GTP-dependent recruitment of CIITA to the class II major histocompatibility complex promoter. J Biol Chem (2007) 0.92
Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol (2010) 0.92
A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2005) 0.91
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol (2014) 0.91
MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol (2007) 0.91
Predictors of indoor air concentrations in smoking and non-smoking residences. Int J Environ Res Public Health (2010) 0.91
Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases. J Biol Chem (2005) 0.90
Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol (2002) 0.90
EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol (2011) 0.90
Windsor, Ontario exposure assessment study: design and methods validation of personal, indoor, and outdoor air pollution monitoring. J Air Waste Manag Assoc (2011) 0.90
PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells. J Immunol (2009) 0.90
TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett (2009) 0.89
Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res (2012) 0.89
Cortical responses to visual motion in alert and anesthetized monkeys. Nat Neurosci (2003) 0.89
Immune tolerance in breast cancer. Breast Dis (2004) 0.88
Determination of volatile organic compounds in different microenvironments by multibed adsorption and short-path thermal desorption followed by gas chromatographic-mass spectrometric analysis. J Chromatogr A (2005) 0.87
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control (2012) 0.86
PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res (2010) 0.86
The effect of scale-free topology on the robustness and evolvability of genetic regulatory networks. J Theor Biol (2010) 0.86
Windsor, Ontario exposure assessment study: design and methods validation of personal, indoor, and outdoor air pollution monitoring. J Air Waste Manag Assoc (2011) 0.86
Personal exposure to specific volatile organic compounds and acute changes in lung function and heart rate variability among urban cyclists. Environ Res (2012) 0.85
Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology (2005) 0.84
Co-expression of estrogen receptor-alpha and targets of estrogen receptor action in proliferating monkey mammary epithelial cells. Breast Cancer Res (2006) 0.84
Accounting for network effects in neuronal responses using L1 regularized point process models. Adv Neural Inf Process Syst (2010) 0.83
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.82
Epigenetic regulation of a brain-specific glycosyltransferase N-acetylglucosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. J Biol Chem (2014) 0.82
Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res (2013) 0.82
Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer. J Clin Oncol (2013) 0.82
Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma (2012) 0.81
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leuk Res (2011) 0.79